The GLP-1 Crisis in Formation
A clinically grounded parallel to the opioid epidemic — and why the window to act is now
THE THREE-STAGE DEPENDENCY TRAP
Lean Mass Destruction
25–40% of weight lost on GLP-1 is muscle, not fat. The scale shows progress. The biology is deteriorating. No monitoring system flags the divergence.
of weight loss is lean mass (STEP-1 trial)
Metabolic Suppression
Resting metabolic rate falls with lean mass loss. Thyroid downregulates. The patient's body recalibrates to a lower energy expenditure baseline — a clinically underappreciated consequence of GLP-1 discontinuation.
proportional to lean mass lost
The No-Exit Scenario
60% of weight lost is regained within 12 months of stopping — 4× faster than it was lost. The returning weight is fat, not muscle. The patient is now more sarcopenic and more at risk than before treatment.
higher CVD risk with sarcopenic obesity
POST-DISCONTINUATION BODY COMPOSITION TRAJECTORY
Index = 100 at discontinuation. Lean mass falls; fat mass and metabolic suppression worsen over 24 months.
- Lean Mass Index
- Fat Mass Index
- Metabolic Rate Index
The Oral GLP-1 Amplifier — Orforglipron (FDA Decision Q2 2026)
Eli Lilly's orforglipron — a once-daily oral GLP-1 — has an FDA decision expected Q2 2026 (Reuters, March 4, 2026). Removing the injection barrier is projected to bring 5–10 million new patients into the market within 12 months. These first-time users will skew toward primary care patients with no existing monitoring relationship — precisely the population most at risk of entering the dependency trap undetected. The Guard Rail was designed for exactly this patient.
The Metabolic Guard Rail
Market Intelligence Dashboard
A B2B2C clinical safety infrastructure that protects GLP-1 and bariatric patients from biological bankruptcy — partnering with weight loss clinics, not competing with them. No prescribing. No clinical decisions. Just objective biological monitoring that every serious weight loss practice will eventually require.
The Business Model: B2B2C Safety Infrastructure
We don't compete with weight loss clinics. We make them safer — and we pay them to partner with us.
HOW THE GUARD RAIL WORKS
Surgical / GLP-1 / PCP
Refers patient to Guard Rail. Receives $25/mo admin fee via MSO.
$1,497 BNPL ($125/mo)
Oura Ring, Squegg, Stelo CGM, Renpho tape, lab panel.
Composite Score 0–100
Four biological pillars synthesized into a single alert score.
5–10 min/patient/mo
Prescribing physician co-signs data. Guard Rail never prescribes.
The Guard Rail issues zero prescriptions. All clinical decisions remain with the patient's existing treating physician. This is a data platform, not a clinical practice.
Weight loss clinics, bariatric surgeons, and primary care physicians are distribution partners. The Guard Rail makes their patients safer and pays them $25/month per enrolled patient.
The patient pays the $1,497 audit and $99–$197/month subscription. The clinic receives passive administrative revenue and improved patient retention — with zero additional overhead.
The Hardware-Inclusive Audit Kit
$1,497 BNPL ($125/mo via Affirm) — patient keeps all hardware permanently
KIT COST BREAKDOWN vs. REVENUE
AUDIT KIT COMPONENTS
Continuous HRV, resting heart rate, sleep quality — autonomic tone pillar
Clinical grip strength testing — structural power pillar
OTC FDA-cleared continuous glucose — glycemic efficiency pillar
Waist-to-height ratio for visceral fat proxy — metabolic engine pillar
rT3, Fasting Insulin, IGF-1, Albumin, CBC, CMP — metabolic engine pillar
Before operational overhead · ~50% gross margin
THE OUTLAW INDEX — FOUR BIOLOGICAL PILLARS
Squegg grip strength + Sit-to-Stand reps
Type II muscle fiber integrity
7-day trailing HRV + resting heart rate via Oura
CNS resilience & physiological stress load
CGM variability + time-in-range via Stelo
Fuel utilization & insulin sensitivity
rT3 / Fasting Insulin / IGF-1 / Waist:Height ratio
Thyroid function, anabolic floor, visceral fat
The Physician Partnership Model
The clinic earns passive revenue. The patient gets safety. The Guard Rail gets distribution.
CLINIC MONTHLY ADMIN REVENUE ($25/PATIENT)
PHYSICIAN ROLE — CLEARLY DEFINED
Clinic refers patient
Weight loss clinic, bariatric surgeon, or PCP recommends the Guard Rail audit to their existing patient.
Patient completes audit
Patient purchases kit via BNPL, wears hardware, completes lab draw. Results populate the Outlaw Index dashboard.
Physician reviews data
Prescribing physician receives a HIPAA-compliant data report. Reviews and co-signs. Estimated 5–10 minutes per patient per month.
MSO pays admin fee
Guard Rail MSO pays $25/month per enrolled patient to the physician's practice. At 100 patients: $2,500/month passive revenue.
Guard Rail never prescribes
All clinical decisions — dosing, titration, supplementation — remain exclusively with the treating physician. Always.
Strategic Pillar I — Clinic Liability Protection
Documented biometric monitoring transforms the standard of care from indefensible to auditable
Prescription issued with no biological baseline
No muscle mass monitoring at any point
No HRV, thyroid, or anabolic marker tracking
Patient told to 'eat well and exercise'
No documented evidence of active clinical oversight
Adverse outcome = indefensible clinical record
Documented biological baseline at treatment start
Monthly grip strength + HRV + CGM + lab tracking
Every Outlaw Index alert logged and timestamped
Physician co-signature on every monthly report
Auditable trail of active clinical oversight
Adverse outcome = defensible, documented standard of care
Patient safety is the right reason to adopt the Guard Rail. But protecting the practice from legal and regulatory exposure is the reason a busy clinic owner will sign the partnership agreement immediately. The FDA issued 30 warning letters to GLP-1 telehealth platforms in March 2026 for inadequate safety practices. Medical malpractice attorneys are actively examining whether the absence of muscle mass monitoring in rapid weight loss programs constitutes a breach of the evolving standard of care. The Guard Rail is the only platform that provides a documented, timestamped, physician-co-signed monitoring record that constitutes a defensible standard of care.
Strategic Pillar II — Predictive Clinical Intelligence
The Outlaw Index doesn't just detect problems — it tells the physician exactly what to do next
OUTLAW INDEX SIGNAL → PHYSICIAN INTERVENTION MENU
Declining grip strength
Early Type II muscle fiber loss; sarcopenia onset
Falling HRV + rising resting HR
CNS overload; physiological stress exceeding recovery capacity
Rising glucose variability
Impaired insulin sensitivity; fuel utilization dysfunction
Elevated rT3 / Low IGF-1
Thyroid downregulation; anabolic floor collapse
Visceral fat retention despite weight loss
Subcutaneous fat loss pattern; visceral fat persistence
The predictive value of the Outlaw Index increases with every patient enrolled and every month of data collected. Patterns invisible in a cohort of 50 patients become statistically significant at 5,000. The more patients enrolled, the better the algorithm. The better the algorithm, the more compelling the clinical case for enrollment. The more compelling the case, the more clinics partner. This is the classic data flywheel — and it is the foundation of the platform's long-term defensibility and acquisition value.
Strategic Pillar III — Data Ownership & Exit Strategy
The Guard Rail retains all patient data — building the real-world evidence dataset that pharma companies cannot get anywhere else
DATASET VALUE vs. PATIENT COHORT SIZE
ACQUISITION COMPARABLES
Roche · 2018
Longitudinal oncology RWE database (~2.4M patients). Guard Rail builds the metabolic health equivalent.
Public (NYSE) · 2023
Pharma data & CRM platform. Demonstrates the scale of pharma data infrastructure value.
Public (NYSE) · Ongoing
Real-world evidence and health data analytics. The category leader the Guard Rail dataset feeds into.
Every patient biometric, lab result, and Outlaw Index score is retained by the platform. De-identified, aggregated data is the company's most valuable long-term asset.
At 5,000+ patients with 12+ months of longitudinal data, the company begins licensing de-identified datasets to pharmaceutical research teams. Industry benchmarks: $500K–$5M per engagement.
GLP-1 manufacturers (Novo Nordisk, Eli Lilly) and health data companies (IQVIA, Veeva) are the most likely strategic acquirers. Estimated exit range: $50M–$500M+ at Year 5–7.
Flatiron Health built a longitudinal oncology RWE database and was acquired by Roche for $1.9B. The Guard Rail is building the metabolic health equivalent — in a faster-growing therapeutic area.
GLP-1 Market Growth Trajectory
The primary demand driver — $78B today, $170B+ by 2030
PROJECTED MARKET 2030
$170B+
CAGR 12–13%
TAM
~$110B
GLP-1 + Bariatric + RPM Markets (2026)
SAM
~$4.5B
US GLP-1/bariatric patients in organized clinical settings
SOM (Yr 1–3)
~$45–90M
Premium clinical monitoring segment via 50–100 clinic partners
The Clinical Crisis: Skinny Sarcopenia
25–40% of weight lost on GLP-1 therapy is lean muscle mass — not fat
25–40%
of weight lost is lean muscle mass on GLP-1 therapy
NIH PMC, 2025
~40%
lean mass loss in the STEP-1 semaglutide trial specifically
STEP-1 Trial
<100
fellowship-trained obesity medicine doctors in active US practice
STAT News, 2023
67%
of PCPs believe telehealth GLP-1 platforms put patients at risk
2025 PCP Survey
The Biological Bankruptcy Problem: Lean mass loss reduces resting metabolic rate, making weight regain nearly inevitable after discontinuation. Thyroid downregulation further suppresses metabolism. Autonomic strain — measurable via declining HRV — signals systemic physiological stress that conventional weight loss monitoring does not capture. The Guard Rail detects all three, in real time, before they cause irreversible damage or patient dropout.
The Adherence Crisis
52% of GLP-1 patients drop off within 12 months — this is the clinic's revenue problem, and the Guard Rail's opportunity
PATIENT RETENTION AT 12 MONTHS
~48%
n=77,310 patients (AJMC 2025)
The Clinic's Incentive: A patient who discontinues GLP-1 therapy at month 4 is a patient who no longer generates prescription revenue, follow-up visits, or referrals for the clinic. The Guard Rail's monitoring reduces the biological triggers of dropout — making it a patient retention tool for the clinic, not just a safety tool for the patient.
Competitive Positioning
Clinical depth vs. metabolic monitoring specificity — the Guard Rail occupies a unique quadrant
FEATURE COMPARISON
| Platform | Muscle | HRV | CGM | Lab Panel | Physician Fee | No Prescribing | $/mo |
|---|---|---|---|---|---|---|---|
| Ro / Hims & Hers | ✗ | ✗ | ✗ | Basic | ✗ | ✓ | $99–145 |
| Calibrate | ✗ | ✗ | ✗ | Annual | ✗ | ✗ | $199 |
| Noom GLP-1 | ✗ | ✗ | ✗ | ✗ | ✗ | ✗ | $70 |
| Levels Health | ✗ | ✗ | ✓ | Optional | ✗ | ✓ | $24+ |
| Guard Rail ★ | ✓ Squegg | ✓ Oura | ✓ Stelo | rT3/IGF-1 | $25/mo | ✓ Always | $99–197 |
Financial Model & MRR Projections
Three-stream revenue: Audit Kit + Monthly Subscription + Physician Admin Fee (MSO)
PROJECTED MRR AT MONTH 24
$128K/mo
1,000 active patients
Hardware-Inclusive Audit
Patient receives Oura Ring, Squegg, Stelo CGM (1mo), Renpho tape, and full lab panel. BNPL via Affirm at $125/mo. Hardware belongs to patient permanently.
Monthly Subscription
Tier 1 ($99): Monthly Outlaw Index report shared with physician. Tier 2 ($197): Real-time alerts + priority physician notification when score drops below threshold.
Physician Admin Fee (MSO)
Guard Rail MSO pays the clinic $25/month per enrolled patient for data review and co-signature. Creates alignment, reduces churn, incentivizes clinic referrals.
Digital Health Tailwinds
Three enabling markets growing in parallel — all converging on the Guard Rail's use case
- RPM Market ($B)
- CGM Market ($B)
- Wearable Health ($B)
Regulatory Strategy
Designed from the ground up to stay on the right side of every regulatory boundary
MSO owns the technology and marketing. PC employs the reviewing physicians. Standard digital health architecture for multi-state compliance with Corporate Practice of Medicine laws.
Outlaw Index is an informational dashboard, not a diagnostic tool. Jan 2026 FDA guidance explicitly permits HRV, glucose, and grip strength monitoring as general wellness. Physician makes all clinical decisions.
The Guard Rail's most important regulatory protection is architectural: it is physically incapable of issuing prescriptions. The prescribing physician is always the patient's existing treating provider.
FDA issued 30 warning letters to GLP-1 telehealth platforms in Mar 2026 for marketing compounded medications. Guard Rail does not prescribe, dispense, or market any medications. Zero exposure.
Interactive Revenue Calculator
Drag the slider and toggle scenarios to model Year 1 revenue at any enrollment level
SCENARIO
Gross Revenue (Y1)
$2.09M
audit + subscriptions
Net Revenue (Y1)
$1.20M
after COGS + phys fees
Audit Gross Profit
$760K
1,000 × $760
Year-End MRR
$99K
$99/mo × patients
Net MRR
$74K
after $25 phys fee
Net Margin
57.6%
blended Y1
Conservative = 0.6× input · Base = 1.0× input · Optimistic = 1.6× input · Avg 6 months subscription billed in Y1
Traction, Validation & The Ask
What exists today, what the investment enables, and what the 12-month milestones look like
CURRENT VALIDATED ASSETS
2 Clinic Pilots Committed
Two weight loss clinics have expressed willingness to pilot the platform with their patients — providing an immediate, low-cost real-world validation pathway.
App in Development
Proof-of-concept mobile application under development through SJL Innovations. Awaiting final cost estimate for completion to deployable state.
Hardware Stack Costed
All four hardware components (Oura, Squegg, Stelo, Renpho) selected, priced, and validated. Lab panel supplier relationships identified.
Revenue Model Validated
Four-stream revenue architecture (audit, subscription, physician admin fee, pharma data licensing) stress-tested against current market pricing and competitor benchmarks.
Clinical Evidence Base
Peer-reviewed literature confirms the lean mass loss crisis, the adherence failure rate, and the absence of comprehensive monitoring solutions.
Regulatory Path Cleared
MSO-PC structure identified. FDA wellness/SaMD boundary mapped. No-prescribing architecture eliminates the highest-risk regulatory exposure.
Data Ownership Strategy Defined
Pharmaceutical licensing exit pathway modeled against Flatiron Health comparable ($1.9B acquisition by Roche). De-identification protocol and HIPAA Safe Harbor compliance mapped.
The company is seeking seed-stage investment to fund two primary objectives: completion of the SJL Innovations app proof-of-concept to a clinic-deployable state, and hiring a dedicated marketing professional to build the B2B clinic acquisition pipeline. The two committed pilot clinics provide an immediate, low-cost validation pathway. The investment required to activate these pilots and build the marketing function is modest relative to the revenue potential — a characteristic that makes this an attractive early-stage opportunity.
SJL Innovations proof-of-concept to deployable clinic-ready state
Dedicated B2B clinic acquisition and partnership development
Hardware procurement and onboarding for 2 committed pilot clinics
12-MONTH MILESTONES (POST-FUNDING)
Marketing hire onboarded; B2B clinic outreach pipeline launched
App proof-of-concept deployed to 2 committed pilot clinics
First 25 patients enrolled; Outlaw Index scoring live
5 additional clinic partnerships signed; 75 active patients
100 active patients; MRR ~$12.8K; pilot cohort data analysis begins
Outlaw Index v1.0 validated on pilot data; Series A preparation begins
Data licensing strategy formalized; initial pharma conversations initiated